Analysis for the Recurrence of Meningiomas Using C-Methionine PET

• Published in: Journal of Neurological Surgery Part B: Skull Base Vol. 73; no. S 02
• Main Authors: Ikeda, H., Tsuyuguchi, N., Kunihiro, N., Uda, T., Goto, T., Takami, T., Ishibashi, K., Ohata, K.
• Format: Conference Proceeding Journal Article
• Language: English
• Published: 01.06.2012
• ISSN: 2193-6331; 2193-634X
• DOI: 10.1055/s-0032-1314219

Objective: Meningiomas are usually treated with surgery, but the recurrence rate is not low even if gross total resection is performed. In some cases, we take a wait-and-see approach because of the tumor size, tumor location, or the patient's condition. It is important to assess the possibility of tumor recurrence for the postoperative cases or the risk of the tumor growth for the follow-up cases. Methods: Forty patients (15 men and 25 women) with intracranial meningiomas who underwent C-methionine (MET) PET before treatment from 1995 to 2010 were enrolled. We performed surgical resection for 35 patients (gross total resection in 20 cases, subtotal resection in13 cases, partial resection in 1 case, biopsy in 1 case), and took a wait-and-see approach for 5 patients. We evaluated the characteristics, the histopathology, Ki-67 labeling index (LI), and lesion-to-normal ratio (LN ratio) of MET uptake. Results: The extent of tumor resection and brain invasion were the significant risk factors for recurrence. The tumor location of the skull base was not a significant risk factor. The LN ratio of MET uptake was significantly higher in the recurrent cases than in the nonrecurrent cases. The Ki-67 LI tended to be higher in the recurrent cases than in the nonrecurrent cases, but there was no significant difference. Conclusions: The high LN ratio of the MET uptake was one of the risk factors for tumor recurrence. The LN ratio of MET uptake before treatment might be one of the decisive factors for surgical resection or additional treatment.